{"id":958811,"date":"2026-05-06T07:34:02","date_gmt":"2026-05-06T11:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/"},"modified":"2026-05-06T07:34:02","modified_gmt":"2026-05-06T11:34:02","slug":"briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/","title":{"rendered":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1\/2a clinical study for Bria-BRES+ in metastatic breast cancer<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Bria-BRES+ is BriaCell\u2019s next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1\/2a clinical study in metastatic breast cancer in the coming months<\/em><br \/>\n          <\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, May  06, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report it has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for metastatic breast cancer.<\/p>\n<p align=\"justify\">\u201cWe are honored to announce FDA clearance of the first IND for our next generation personalized immunotherapy, Bria-BRES+,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cThe unique design of Bria-BRES+ offers the potential for a favorable safety profile and meaningful therapeutic benefit in metastatic breast cancer. We look forward to advancing Bria-BRES+ into the clinic as we seek to bring new hope to these patients who have few to no effective treatment options.\u201d<\/p>\n<p align=\"justify\">As <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eOvYa-Ta7IXt8GMl5CFyio4VbnznVawKfI-Zu959q6FEJuOjtYxXlyqxbSpoOlGqwk9ReTLeDEVPswaqZId9LIx99SRjI-NG5H377h-ImEv93FPuxYjPguQIclFfSDns73EIobOa-Pr2BrTreNZ22w7Bbm0yhvWWZ74jTcgD39bV_m1XHBxE4pQX9IJ11mK9ukAzN8qlvH_qexdkRKy279Z54gAiJRCvNbEUpQgjsuK1UmD07_P_9lXk9HJxFN89\" rel=\"nofollow\" target=\"_blank\">reported in BriaCell\u2019s recent AACR preclinical poster presentation<\/a>, Bria-BRES+ demonstrated activation of both adaptive and innate immunity including activation of na\u00efve (resting) T-cells, dendritic cells and natural killer (NK) cells. BriaCell believes this multipronged immune activation may enhance clinical efficacy and help prevent immune escape in patients with metastatic breast cancer.<\/p>\n<p align=\"justify\">BriaCell\u2019s Bria-BRES+ builds on its Bria-OTS\u2122 breast cancer clinical program, where the first patient dosed experienced the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hi3Uem6dEj0XlNKbwfUvNKyF2W7aL79SdRRbD73TR4ZdMNy1xTsBc6ZV0tJq4vI_tNxf_C3GO5B5IkGp-XIPY8sFYk2v2bpIe0c_w1b2nzsyZTBJ4JXDtOro7WmfaRWmvdFIMEeYC1jx19_rve_shzg0s0TZs4cue5shmzxKYUlBUpObc6DNLTmY9I0mvfVCBMFfFsVoap7QIYH9_QeonqHPF_WcUAYckYy0V9_Zo04=\" rel=\"nofollow\" target=\"_blank\">sustained complete resolution of a lung metastasis<\/a>. This 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response of the lesion, initially observed at 2 months, was subsequently confirmed at 4 months, 6 months, and at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.<\/p>\n<p align=\"justify\">\n        <strong>Figure 1: As <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dGH007qnGkKHNew-9-InleMEh3kyejs0UDcqw5-J2vIbmrvtGOivkUhY64-zzFmaTCEFZSbEJlCt38KgGQSmVtG7TSks1PJON6sfvDkHbRgq9C5CAKSCzt9gCrhf--6IvqytIWWIdhvt0ftDUvg7DLoorb0WoWCSWevfBvQJroAzJ1zdjb4JWo0SoUKP2WwPb14kJ2fFZTDziPY9cwX6yQ==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>previously reported in January 2026,<\/strong><br \/>\n        <\/a><br \/>\n        <strong> treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the right lung of the metastatic breast cancer (MBC) patient following 2 months of therapy and confirmed at 4, 6, and 11 months of therapy<\/strong><br \/>\n        <sup><br \/>\n          <strong>1<\/strong><br \/>\n        <\/sup><br \/>\n        <strong>\u00a0(axial and coronal views)<\/strong>\n      <\/p>\n<p align=\"justify\">\n        \n      <\/p>\n<p align=\"justify\">\n        <sup>1<\/sup>\u00a0Note that the other white dots in the lungs are blood vessels.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N7_6kp3eUfdVCI5CQoqi_ihjzd1o87GRoFVgqPwa0kNssE8yzfeJ8Vrm85i_ua9j9Si-A5_KwaDYYsPdMSAwbaPodgwzC7P4QoWXEHK05Gc=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the FDA clearance of the IND application and the planned initiation of a Phase 1\/2a clinical study of Bria\u2011BRES+, and expectations regarding the potential clinical benefits of the Bria\u2011OTS+ platform, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company&#8217;s most recent Management\u2019s Discussion and Analysis, under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company&#8217;s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QPfLUhqQmn5eET_QJiql6dRTCStFPQQlWGYNhIM6LLU--dA3AtJ_8thC_tJgu0iEhUBuFPKpaxM0SP8jQ5hhZ9x-xCWPyrF1Fdeyy-7ePkE=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/u><\/strong>\u00a0and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QPfLUhqQmn5eET_QJiql6UWMDfiDL2nmCBdwN1Q_VFyfCOt_K8vpNa5R0IBZsAjUMVVQxIkzGgEKGjJ3dtQUmQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ND8rPkm7-qxxWMgUVMbALn2y1W70PgkcCsmxiG013bjA0a7IEwNK5EhiCgtfqUFesK4zJ2ySVXfaGippfC3H7I9dFzad-vmSMPfyPrvQfc8=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A-fwAITjupwHkzz9Sa98GeWLfxmBDfsMwSlVDnrTPIvKtGG2PL8tTuMz468x7LKd535BM_HCmvChyHjMNBScMe0LAcVcfK71JLihlJeOfpY=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N7_6kp3eUfdVCI5CQoqi_pDHdEe0qPR7gmIX1dSu3i0RgymlPgTo2ozYDAavJ6wpa4AkK6oLvGHiiH3OX5nkasn9KgbSSV1682Ya2K2_zdVb16Oy1tkS6Iswfz7JheM8mmDxt1ogA_sn3tvxTU9tQn5c_qEmVQ7KMjSZr9oXrBelhUaFiCH32kt54FfIYOPNkK_30WYWQhlpYaZx72AP1K5y2teYKty0lm5EYqtOLTgoG1V6YU-w_dPB-_BdULOBFraFECr781g8fyWX6sAupQ==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/cf1af19a-fd92-49b4-8e39-fb9b1c4191a7<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTczYTBmZTQtYjYzNi00YzY4LWJiOWYtNWYxOTBhOTJlNmZiLTExMDIyMjktMjAyNi0wNS0wNi1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1\/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell\u2019s next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1\/2a clinical study in metastatic breast cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report it has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958811","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1\/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell\u2019s next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1\/2a clinical study in metastatic breast cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report it has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, &hellip; Continue reading &quot;BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T11:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer\",\"datePublished\":\"2026-05-06T11:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/\"},\"wordCount\":794,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/\",\"name\":\"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\",\"datePublished\":\"2026-05-06T11:34:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk","og_description":"FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1\/2a clinical study for Bria-BRES+ in metastatic breast cancer Bria-BRES+ is BriaCell\u2019s next generation personalized immunotherapy for breast cancer, and features additional immune activating components designed to enhance clinical efficacy BriaCell has prepared clinical supplies of Bria-BRES+ and plans to initiate a Phase 1\/2a clinical study in metastatic breast cancer in the coming months PHILADELPHIA and VANCOUVER, British Columbia, May 06, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report it has received FDA clearance to initiate clinical evaluation of Bria-BRES+, its next generation, personalized, &hellip; Continue reading \"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-06T11:34:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer","datePublished":"2026-05-06T11:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/"},"wordCount":794,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/","name":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=","datePublished":"2026-05-06T11:34:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkzNiM3NTg0OTM5IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+\u2122 Clinical Study in Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958811"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958811\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}